CDH1 and carcinoma: Of particular significance, the downregulation of E-cadherin is a prominent feature of many carcinomas, including breast (Vergara et al., 2015), squamous cell lung (Zhang et al., 2013), endometrial (Feng et al., 2013), and prostate (Barber et al., 2015) cancer.